A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

• Sarit Assouline,
• Biljana Culjkovic-Kraljacic,
• Julie Bergeron,
• Stephen Caplan,
• Eftihia Cocolakis,
• Caroline Lambert,
• Cara J. Lau,
• Hiba Ahmad Zahreddine,
• Wilson H. Miller,
• Katherine L. B. Borden

Affiliations

Sarit Assouline

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Biljana Culjkovic-Kraljacic

Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal

Julie Bergeron

Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada

Stephen Caplan

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Eftihia Cocolakis

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Caroline Lambert

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Cara J. Lau

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Hiba Ahmad Zahreddine

Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal

Wilson H. Miller

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University

Katherine L. B. Borden

Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal